S&P 500   4,217.92 (-1.64%)
DOW   32,928.69 (-1.51%)
QQQ   354.22 (-1.95%)
AAPL   171.79 (-1.13%)
MSFT   312.18 (-2.99%)
META   301.04 (-1.88%)
GOOGL   132.30 (-1.39%)
AMZN   124.60 (-3.75%)
TSLA   247.97 (-1.44%)
NVDA   435.31 (-2.79%)
NIO   8.67 (-1.37%)
BABA   84.37 (-2.50%)
AMD   100.08 (-3.09%)
T   14.72 (+0.34%)
F   12.05 (-2.11%)
MU   67.89 (-0.10%)
CGC   0.69 (-6.87%)
GE   107.34 (-1.33%)
DIS   79.57 (-2.57%)
AMC   8.08 (-0.86%)
PFE   33.88 (-0.18%)
PYPL   57.46 (-1.88%)
NFLX   375.25 (-1.34%)
S&P 500   4,217.92 (-1.64%)
DOW   32,928.69 (-1.51%)
QQQ   354.22 (-1.95%)
AAPL   171.79 (-1.13%)
MSFT   312.18 (-2.99%)
META   301.04 (-1.88%)
GOOGL   132.30 (-1.39%)
AMZN   124.60 (-3.75%)
TSLA   247.97 (-1.44%)
NVDA   435.31 (-2.79%)
NIO   8.67 (-1.37%)
BABA   84.37 (-2.50%)
AMD   100.08 (-3.09%)
T   14.72 (+0.34%)
F   12.05 (-2.11%)
MU   67.89 (-0.10%)
CGC   0.69 (-6.87%)
GE   107.34 (-1.33%)
DIS   79.57 (-2.57%)
AMC   8.08 (-0.86%)
PFE   33.88 (-0.18%)
PYPL   57.46 (-1.88%)
NFLX   375.25 (-1.34%)
S&P 500   4,217.92 (-1.64%)
DOW   32,928.69 (-1.51%)
QQQ   354.22 (-1.95%)
AAPL   171.79 (-1.13%)
MSFT   312.18 (-2.99%)
META   301.04 (-1.88%)
GOOGL   132.30 (-1.39%)
AMZN   124.60 (-3.75%)
TSLA   247.97 (-1.44%)
NVDA   435.31 (-2.79%)
NIO   8.67 (-1.37%)
BABA   84.37 (-2.50%)
AMD   100.08 (-3.09%)
T   14.72 (+0.34%)
F   12.05 (-2.11%)
MU   67.89 (-0.10%)
CGC   0.69 (-6.87%)
GE   107.34 (-1.33%)
DIS   79.57 (-2.57%)
AMC   8.08 (-0.86%)
PFE   33.88 (-0.18%)
PYPL   57.46 (-1.88%)
NFLX   375.25 (-1.34%)
S&P 500   4,217.92 (-1.64%)
DOW   32,928.69 (-1.51%)
QQQ   354.22 (-1.95%)
AAPL   171.79 (-1.13%)
MSFT   312.18 (-2.99%)
META   301.04 (-1.88%)
GOOGL   132.30 (-1.39%)
AMZN   124.60 (-3.75%)
TSLA   247.97 (-1.44%)
NVDA   435.31 (-2.79%)
NIO   8.67 (-1.37%)
BABA   84.37 (-2.50%)
AMD   100.08 (-3.09%)
T   14.72 (+0.34%)
F   12.05 (-2.11%)
MU   67.89 (-0.10%)
CGC   0.69 (-6.87%)
GE   107.34 (-1.33%)
DIS   79.57 (-2.57%)
AMC   8.08 (-0.86%)
PFE   33.88 (-0.18%)
PYPL   57.46 (-1.88%)
NFLX   375.25 (-1.34%)
NASDAQ:AKBA

Akebia Therapeutics (AKBA) Stock Forecast, Price & News

$1.08
-0.07 (-5.65%)
(As of 02:04 PM ET)
Compare
Today's Range
$1.07
$1.13
50-Day Range
$1.12
$1.84
52-Week Range
$0.24
$1.84
Volume
862,654 shs
Average Volume
1.88 million shs
Market Capitalization
$204.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.75

Akebia Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
247.2% Upside
$3.75 Price Target
Short Interest
Bearish
3.84% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.35
Upright™ Environmental Score
News Sentiment
0.45mentions of Akebia Therapeutics in the last 14 days
Based on 18 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.35) to ($0.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

657th out of 976 stocks

Pharmaceutical Preparations Industry

304th out of 447 stocks


AKBA stock logo

About Akebia Therapeutics (NASDAQ:AKBA) Stock

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

AKBA Price History

AKBA Stock News Headlines

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Akebia Therapeutics Resubmits NDA For Vadadustat To FDA
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)
“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”
AKBA Akebia Therapeutics, Inc.
Q2 2023 Akebia Therapeutics Inc Earnings Call
Akebia Therapeutics Posts Loss In Q2; Net Product Revenue Down 2.5%
Akebia Therapeutics Expects To Resubmit NDA For Vadadustat NDA In Q3
See More Headlines
Receive AKBA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKBA Company Calendar

Last Earnings
8/25/2023
Today
10/03/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKBA
Employees
204
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.75
High Stock Price Forecast
$3.75
Low Stock Price Forecast
$3.75
Forecasted Upside/Downside
+226.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-94,230,000.00
Pretax Margin
-49.16%

Debt

Sales & Book Value

Annual Sales
$201.00 million
Book Value
$0.03 per share

Miscellaneous

Free Float
181,083,000
Market Cap
$216.56 million
Optionable
Optionable
Beta
0.83
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. John P. Butler MBAMr. John P. Butler MBA (Age 59)
    CEO, Pres & Director
    Comp: $1.29M
  • Mr. Michel  DahanMr. Michel Dahan (Age 44)
    Sr. VP & COO
    Comp: $734.73k
  • Ms. Nicole R. Hadas J.D. (Age 50)
    Sr. VP, Chief Legal Officer & Sec.
    Comp: $687.38k
  • Dr. Steven Keith BurkeDr. Steven Keith Burke (Age 62)
    Sr. VP of R&D and Chief Medical Officer
    Comp: $766.57k
  • Ms. Ellen E. Snow CPA (Age 51)
    CGMA, Sr. VP, CFO, Treasurer & Principal Accounting Officer
  • Tracey Vetterick
    VP of Portfolio Strategy & Corp. Admin.
  • Mercedes Carrasco
    Director of Corp. Communications
  • Mr. Douglas Jermasek M.B.A. (Age 62)
    VP of Marketing & Strategy
  • Ms. Meredith Bowman
    Sr. VP of People
  • Ms. Kimberly Garko
    Sr. VP of Quality, Manufacturing & Pharmaceutical Devel.













AKBA Stock - Frequently Asked Questions

Should I buy or sell Akebia Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKBA shares.
View AKBA analyst ratings
or view top-rated stocks.

What is Akebia Therapeutics' stock price forecast for 2023?

2 Wall Street research analysts have issued 1 year price objectives for Akebia Therapeutics' stock. Their AKBA share price forecasts range from $3.75 to $3.75. On average, they expect the company's share price to reach $3.75 in the next twelve months. This suggests a possible upside of 226.1% from the stock's current price.
View analysts price targets for AKBA
or view top-rated stocks among Wall Street analysts.

How have AKBA shares performed in 2023?

Akebia Therapeutics' stock was trading at $0.5770 at the beginning of 2023. Since then, AKBA shares have increased by 99.3% and is now trading at $1.15.
View the best growth stocks for 2023 here
.

Are investors shorting Akebia Therapeutics?

Akebia Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 7,230,000 shares, an increase of 24.4% from the August 31st total of 5,810,000 shares. Based on an average daily volume of 1,760,000 shares, the days-to-cover ratio is currently 4.1 days.
View Akebia Therapeutics' Short Interest
.

When is Akebia Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AKBA earnings forecast
.

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) released its quarterly earnings results on Friday, August, 25th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.03. The biopharmaceutical company had revenue of $56.38 million for the quarter, compared to analysts' expectations of $59.10 million. Akebia Therapeutics had a negative net margin of 48.25% and a negative trailing twelve-month return on equity of 249.60%. During the same period in the prior year, the firm posted $0.23 earnings per share.

What ETF holds Akebia Therapeutics' stock ?

Invesco Nasdaq Future Gen 200 ETF holds 33,325 shares of AKBA stock, representing 0.72% of its portfolio.

What is John Butler's approval rating as Akebia Therapeutics' CEO?

28 employees have rated Akebia Therapeutics Chief Executive Officer John Butler on Glassdoor.com. John Butler has an approval rating of 97% among the company's employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

How do I buy shares of Akebia Therapeutics?

Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akebia Therapeutics' stock price today?

One share of AKBA stock can currently be purchased for approximately $1.15.

How much money does Akebia Therapeutics make?

Akebia Therapeutics (NASDAQ:AKBA) has a market capitalization of $216.56 million and generates $201.00 million in revenue each year. The biopharmaceutical company earns $-94,230,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.

How many employees does Akebia Therapeutics have?

The company employs 204 workers across the globe.

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The official website for the company is www.akebia.com. The biopharmaceutical company can be reached via phone at (617) 871-2098, via email at ir@akebia.com, or via fax at 617-871-2099.

This page (NASDAQ:AKBA) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -